Search research articles
Contact Us
Filters
Showing results (231-240 of 237) with videos related to
Page
of 24
Sort By:
You have reached the last page of results.
This site can display upto 237 results.
Communications Biology
|
January 12, 2023
OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases
Gabriel Sturm, Kalpita R Karan, Anna S Monzel, et al.
Nature Aging
|
October 24, 2022
A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking
Albert T Higgins-Chen, Kyra L Thrush, Yunzhang Wang, et al.
Nature Metabolism
|
January 17, 2025
Recommendations for mitochondria transfer and transplantation nomenclature and characterization
Jonathan R Brestoff, Keshav K Singh, Katia Aquilano, et al.
Biorxiv : the Preprint Server for Biology
|
February 19, 2024
A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer's disease
Verena Haage, John F Tuddenham, Natacha Comandante-Lou, et al.
The Lancet. Oncology
|
August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Trends in Endocrinology and Metabolism: TEM
|
October 10, 2024
A platform to map the mind-mitochondria connection and the hallmarks of psychobiology: the MiSBIE study
Catherine Kelly, Caroline Trumpff, Carlos Acosta, et al.
Science (New York, N.Y.)
|
June 8, 2023
Taurine deficiency as a driver of aging
Parminder Singh, Kishore Gollapalli, Stefano Mangiola, et al.
Page
of 24
Search research articles
Search
Showing results (231-240 of 237) with videos related to
Sort By:
Page
of 24
You have reached the last page of results.
This site can display upto 237 results.
Communications Biology
|
January 12, 2023
OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases
Gabriel Sturm, Kalpita R Karan, Anna S Monzel, et al.
Nature Aging
|
October 24, 2022
A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking
Albert T Higgins-Chen, Kyra L Thrush, Yunzhang Wang, et al.
Nature Metabolism
|
January 17, 2025
Recommendations for mitochondria transfer and transplantation nomenclature and characterization
Jonathan R Brestoff, Keshav K Singh, Katia Aquilano, et al.
Biorxiv : the Preprint Server for Biology
|
February 19, 2024
A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer's disease
Verena Haage, John F Tuddenham, Natacha Comandante-Lou, et al.
The Lancet. Oncology
|
August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Trends in Endocrinology and Metabolism: TEM
|
October 10, 2024
A platform to map the mind-mitochondria connection and the hallmarks of psychobiology: the MiSBIE study
Catherine Kelly, Caroline Trumpff, Carlos Acosta, et al.
Science (New York, N.Y.)
|
June 8, 2023
Taurine deficiency as a driver of aging
Parminder Singh, Kishore Gollapalli, Stefano Mangiola, et al.
Page
of 24